title: Clodronate in the prevention and treatment of skeletal metastasis.
abstract: Many solid tumors, including breast and prostate cancer, metastasize to bone, thereby putting patients at high risk for developing skeletal complications including pathologic fracture, spinal cord compression and debilitating bone pain. Patients often live for many years after developing bone metastasis, a fact that highlights the importance of therapies to reduce morbidity from skeletal complications. Bisphosphonates, including clodronate, have been shown to be useful in reducing skeletal complications in patients with cancer. This review will highlight the role of clodronate for skeletal metastasis.
authors.affiliation: National Cancer Institute, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, 10 Center Drive, 8B07 MSC 1750, Bethesda, MD 20892, USA. gulleyj@mail.nih.gov
authors.forename: James
authors.initials: J
authors.lastname: Gulley
authors.forename: William L
authors.initials: WL
authors.lastname: Dahut
mesh_terms: D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000517:prevention & control* / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology; D002986:Clinical Trials as Topic; D004002:Clodronic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D009017:Morbidity; D011471:Prostatic Neoplasms / Q000473:pathology; D012307:Risk Factors
chemical_list: D050071:Bone Density Conservation Agents; D004002:Clodronic Acid